Today, FDA issued the Federal Register discover, Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence, to encourage the submission of supplemental new drug functions to switch the labeling statements for buprenorphine-containing transmucosal merchandise for the therapy of opioid dependence (BTODs). 
 
BTODs are medicines which are dissolved within the mouth and include buprenorphine, or a mixture of buprenorphine and naloxone, and are indicated to deal with opioid use dysfunction (OUD)—beforehand known as opioid dependence.

FDA has acquired suggestions from a number of events (e.g., well being care practitioners, sufferers, skilled societies), indicating a misperception by some that labeling for BTODs features a most every day dose when, the truth is, the labeling doesn’t specify a most dose. We additionally acquired related suggestions by way of a number of conferences through which FDA participated, together with a two-day public meeting with the Reagan-Udall Foundation for the FDA in May 2023 and two listening sessions led by the Substance Abuse and Mental Health Services Administration (SAMHSA) in November and December 2023. For this cause, FDA is recommending revisions to BTOD labeling to keep away from misinterpretation of dosing data. 

“Current BTOD labeling has been misinterpreted by some as suggesting a most dosage of 16 or 24 milligrams (mg) every day though the labeling doesn’t explicitly present a most dosage,” stated Marta Sokolowska, Ph.D., deputy middle director for Substance Use and Behavioral Health on the Center for Drug Evaluation and Research. “Our suggestions search to make clear, by way of the labeling, that every day upkeep dosages may be incrementally adjusted for every affected person primarily based upon their particular person therapeutic want and that every day doses increased than 24 mg per day could also be acceptable for some sufferers.” 

The really useful labeling adjustments are meant for transmucosal buprenorphine merchandise solely, resembling Suboxone, Zubsolv, and different generic transmucosal buprenorphine medicines. The really useful adjustments intend to make clear that neither 16 mg/day nor 24 mg/day must be interpreted as most dosages for these medicines and to offer extra labeling suggestions together with:

• Removing the phrase “goal dose” from the labeling; and
• Modifying the prevailing assertion, “Dosages increased than 24 mg every day haven’t been demonstrated to offer a scientific benefit,” to learn, “Dosages increased than 24 mg buprenorphine every day haven’t been investigated in randomized scientific trials however could also be acceptable for some sufferers.”

“We stand with FDA’s suggestion to replace the labeling for BTODs,” stated Yngvild Ok. Olsen, MD, MPH, director for the Center for Substance Abuse Treatment at SAMHSA. “The function these medicines play in saving lives and permitting individuals with OUD to thrive and obtain well-being is super. Updated labeling will assist extra practitioners present transmucosal buprenorphine-containing medicines in a person-centered method that facilitates retention in efficacious therapy.” 

Today’s motion follows a number of prior FDA actions concerning buprenorphine and therapy for OUD, together with issuing a joint letter with SAMHSA in May 2023 to make clear the significance of counseling and different companies as a part of a complete therapy plan, in addition to reiterating that offering buprenorphine shouldn’t be made contingent upon participation in such companies; approving a new buprenorphine treatment option for OUD in May 2023; and launching a campaign to tell, encourage, and supply sources to prescribers using remedy to deal with OUD in May 2024. 

Together, these actions help in propelling FDA ahead in implementing the FDA Overdose Prevention Framework, which supplies our imaginative and prescient to undertake impactful, artistic actions to encourage hurt discount and innovation in decreasing managed substance-related overdoses and deaths. As we proceed executing that imaginative and prescient, we stay targeted on responding to all sides of substance use, misuse, overdose, and demise by way of the 4 priorities of the framework, together with: supporting major prevention by eliminating pointless preliminary prescription drug publicity and inappropriate extended prescribing; encouraging hurt discount by way of innovation and schooling; advancing improvement of evidence-based therapies for substance use problems; and defending the general public from unapproved, diverted, or counterfeit medicine presenting overdose dangers.

Additional Resources: